
In this episode of The BioHub by Avetix, I’m joined by Paul Hastings, CEO of Nkarta.Paul has spent more than three decades in biotech, leading companies across oncology, rare disease and cell therapy, while also becoming one of the industry’s most prominent patient advocates. At Nkarta, he’s now leading the development of allogeneic NK cell therapies designed to make cell therapy safer, more scalable and more accessible.We discuss the evolution of biotech since Paul entered the industry in 1989, the future of cell therapy, the challenges of scaling access, the US clinical and regulatory environment, the importance of patient advocacy, and the mentors and lessons that have shaped his career.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Episode 243 - Johanna Kaufman: CSO at DeckBio

Episode 242 - Sam Blackman

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

Episode 240 - Inder Kaul - CMO at Draig Therapeutics
Free AI-powered recaps of The BioHub - by Avetix and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.